Over two decades after the introduction of cardiac resynchronization therapy (CRT) into
clinical practice,∼ 30% of candidates continue to fail to respond to this highly effective …

Heart failure (HF) is a heterogeneous syndrome affecting more than 60 million individuals
globally. Despite recent advancements in understanding of the pathophysiology of HF, many …

Background Cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) is well-
established therapy in patients with reduced left ventricular ejection fraction (LVEF) and …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2011 and includes selected …

Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected
patients in definable populations. The benefits and risks of ICD therapy are directly impacted …

Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart
failure with reduced ejection fraction and leads to improved quality of life, reductions in heart …

Chronic heart failure continues to impose a substantial health-care burden, despite recent
treatment advances. The key pathophysiological process that ultimately leads to chronic …

Background Cardiac resynchronization therapy (CRT) is one of the most successful heart
failure therapies to emerge in the last 25 years and is applicable to∼ 25–30% of patients …

Aims The aim of the present study was to evaluate the relationship between left ventricular
(LV) electrical delay, as measured by the QLV interval, and outcomes in a prospectively …